Home » Topics » Cancer, BioWorld Science

Cancer, BioWorld Science
RSS

Vion receives an FDA standard review classification for Onrigin NDA

April 24, 2009

Revlimid receives positive final appraisal determination for NHS

April 24, 2009

MK-2206: Development through phase I study described

April 24, 2009

Haptoglobin level a biomarker for gemcitabine-related hematological toxicities

April 24, 2009

Dual inhibitors of PI3K and mTOR with in vivo antitumor activity reported by Piramed and Genentech

April 24, 2009

Semafore achieves proof of concept in design of dual pathway kinase inhibitor SF-2626

April 23, 2009

Preclinical anticancer activity of MEK1 inhibitor E-6201 detailed at AACR

April 23, 2009

Novel, orally active c-MET inhibitor discovered at Lilly: LY-2801653

April 23, 2009

PharmaMar's alkaloid PM-01183 active in vivo, enters phase I investigation

April 23, 2009

Chugai and Roche describe development, preclinical and clinical investigation of CH-4987655

April 23, 2009

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 14, 2026.
AAIC 2026: Age of amyloid is being joined by time of tau
BioWorld
The Alzheimer’s Association International Conference (AAIC) is the world’s biggest dementia conference. And at the AAIC 2026 meeting, there is big buzz around...
Neurovalens granted FDA approval for PTSD therapy for US veterans
BioWorld
Veterans in the U.S. suffering from post-traumatic stress disorder (PTSD) now have access to Neurovalens Ltd.’s Modius Spero, a wearable neuromodulation device,...
News in brief
BioWorld Asia
BioWorld Asia briefs for July 14, 2026
Celia trial: data strong, analysts skeptical
BioWorld
Tuesday brought what was arguably the most anticipated presentation of the 2026 Alzheimer’s Association International Conference when Catherine Mummery, head of...